BRIEF—Darzalex achieves blockbuster status, triggering major milestone payment

Sales of Darzalex (daratumumab) have now topped $1 billion for the year, triggering a $50 million milestone payment to Denmark's Genmab.

The multiple myeloma therapy is indicated in the USA in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.

In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize the drug.

“We continue to be pleased with the rapid uptake seen with Darzalex since its initial launch and approval and are excited to have reached the $1 billion sales milestone,” said Genmab chief executive Jan van de Winkel.